NYSEAMERICAN : CANF
Can-Fite BioPharma Ltd. — Financial statements
Healthcare · Biotechnology · Israel
Last price 1.69 USD (Oct 30, 2026, 8:32 AM EDT) · Market cap 5.22M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Can-Fite BioPharma Ltd. (CANF) reported revenue of 405.00K USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 405.00K | 405.00K | 674.00K | 743.00K | 810.00K | 853.00K |
| Gross Profit | 405.00K | 405.00K | 674.00K | 743.00K | 810.00K | 853.00K |
| Selling, General & Admin | 3.02M | 3.66M | 3.05M | 2.96M | 3.14M | 3.85M |
| Research & Development | 7.12M | 6.69M | 5.76M | 5.98M | 7.76M | 9.85M |
| Operating Expenses | 10.14M | 10.36M | 8.80M | 8.94M | 10.91M | 13.70M |
| Operating Income | -9.73M | -9.95M | -8.13M | -8.20M | -10.10M | -12.84M |
| Interest & Investment Income | 341.00K | 284.00K | 291.00K | 506.00K | 222.00K | 24.00K |
| Currency Exchange Gain (Loss) | -144.00K | -144.00K | -13.00K | 58.00K | -54.00K | 59.00K |
| Other Non Operating Income (Expenses) | -14.00K | -14.00K | -14.00K | -14.00K | -16.00K | -18.00K |
| EBT Excluding Unusual Items | -9.55M | -9.82M | -7.87M | -7.64M | -9.94M | -12.78M |
| Gain (Loss) on Sale of Investments | -4.00K | -4.00K | -14.00K | 11.00K | -229.00K | 162.00K |
| Pretax Income | -9.55M | -9.83M | -7.88M | -7.63M | -10.17M | -12.62M |
| Earnings From Continuing Operations | -9.55M | -9.83M | -7.88M | -7.63M | -10.17M | -12.62M |
| Net Income | -9.55M | -9.83M | -7.88M | -7.63M | -10.17M | -12.62M |
| Preferred Dividends & Other Adjustments | 2.59M | |||||
| Net Income to Common | -9.55M | -9.83M | -7.88M | -7.63M | -10.17M | -15.21M |
| Shares Outstanding (Basic) | 2.93M | 1.65M | 725.31K | 426.11K | 271.91K | 184.36K |
| Shares Outstanding (Diluted) | 2.93M | 1.65M | 725.31K | 426.11K | 271.91K | 184.36K |
| EPS (Basic) | -3.26 | -5.97 | -10.86 | -17.92 | -37.41 | -82.48 |
| EPS (Diluted) | -3.26 | -5.97 | -10.86 | -17.92 | -37.41 | -82.48 |
| Free Cash Flow | -9.51M | -8.95M | -7.64M | -8.44M | -10.81M | -9.87M |
| Free Cash Flow Per Share | -3.24 | -5.44 | -10.54 | -19.81 | -39.76 | -53.53 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | -2,402.96% | -2,456.79% | -1,206.23% | -1,102.96% | -1,246.42% | -1,505.51% |
| Profit Margin | -2,358.76% | -2,426.67% | -1,169.14% | -1,027.46% | -1,255.93% | -1,782.53% |
| Free Cash Flow Margin | -2,348.89% | -2,210.12% | -1,133.83% | -1,136.20% | -1,334.57% | -1,156.98% |
| EBITDA | -9.73M | -9.93M | -8.12M | -8.18M | -10.08M | -12.83M |
| D&A For EBITDA | 2.00K | 24.00K | 7.00K | 15.00K | 14.00K | 14.00K |
| EBIT | -9.73M | -9.95M | -8.13M | -8.20M | -10.10M | -12.84M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 2.98M | 5.53M | 4.83M | 4.28M | 2.98M | 4.39M |
| Short-Term Investments | 4.06M | 3.01M | 3.06M | 4.64M | 5.00M | 14.51M |
| Trading Asset Securities | 8.00K | 237.00K | ||||
| Cash & Short-Term Investments | 7.04M | 8.54M | 7.89M | 8.92M | 7.99M | 19.14M |
| Prepaid Expenses | 960.00K | 826.00K | 1.02M | 908.00K | 1.12M | 881.00K |
| Other Current Assets | 74.00K | 77.00K | 78.00K | 47.00K | 48.00K | |
| Total Current Assets | 8.00M | 9.44M | 8.98M | 9.91M | 9.16M | 20.07M |
| Property, Plant & Equipment | 52.00K | 74.00K | 138.00K | 81.00K | 126.00K | 185.00K |
| Total Assets | 8.05M | 9.51M | 9.12M | 9.99M | 9.28M | 20.25M |
| Accounts Payable | 681.00K | 1.16M | 618.00K | 427.00K | 896.00K | 954.00K |
| Accrued Expenses | 1.09M | 1.11M | 976.00K | 944.00K | 775.00K | 905.00K |
| Current Portion of Leases | 48.00K | 56.00K | 53.00K | 27.00K | 48.00K | 53.00K |
| Current Unearned Revenue | 405.00K | 405.00K | 405.00K | 622.00K | 783.00K | 818.00K |
| Total Current Liabilities | 2.23M | 2.73M | 2.05M | 2.02M | 2.50M | 2.73M |
| Long-Term Leases | 1.00K | 15.00K | 51.00K | 13.00K | 14.00K | 71.00K |
| Long-Term Unearned Revenue | 974.00K | 1.18M | 1.58M | 1.71M | 2.29M | 3.07M |
| Total Liabilities | 3.20M | 3.92M | 3.68M | 3.75M | 4.81M | 5.87M |
| Additional Paid-In Capital | 184.52M | 180.65M | 170.67M | 163.60M | 154.19M | 153.93M |
| Retained Earnings | -180.79M | -176.19M | -166.36M | -158.48M | -150.85M | -140.67M |
| Comprehensive Income & Other | 1.13M | 1.13M | 1.13M | 1.13M | 1.13M | 1.13M |
| Total Common Equity | 4.86M | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
| Shareholders' Equity | 4.86M | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
| Total Liabilities & Equity | 8.05M | 9.51M | 9.12M | 9.99M | 9.28M | 20.25M |
| Total Debt | 49.00K | 71.00K | 104.00K | 40.00K | 62.00K | 124.00K |
| Net Cash (Debt) | 6.99M | 8.47M | 7.78M | 8.88M | 7.92M | 19.02M |
| Net Cash Per Share | 2.38 | 5.14 | 10.73 | 20.84 | 29.15 | 103.14 |
| Filing Date Shares Outstanding | 4.29M | 4.29M | 1.04M | 499.04K | 408.27K | 271.91K |
| Total Common Shares Outstanding | 4.29M | 2.62M | 994.38K | 453.27K | 271.91K | 271.91K |
| Working Capital | 5.78M | 6.71M | 6.93M | 7.89M | 6.66M | 17.34M |
| Book Value Per Share | 1.13 | 2.14 | 5.47 | 13.77 | 16.45 | 52.89 |
| Tangible Book Value | 4.86M | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
| Tangible Book Value Per Share | 1.13 | 2.14 | 5.47 | 13.77 | 16.45 | 52.89 |
| Machinery | 17.00K | 79.00K | 279.00K | 277.00K | 268.00K | |
| Leasehold Improvements | 13.00K | 13.00K | 13.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -9.55M | -9.83M | -7.88M | -7.63M | -10.17M | -12.62M |
| Depreciation & Amortization | 2.00K | 24.00K | 7.00K | 15.00K | 14.00K | 14.00K |
| Loss (Gain) From Sale of Investments | -4.00K | 4.00K | 14.00K | -11.00K | 229.00K | -162.00K |
| Stock-Based Compensation | 181.00K | 340.00K | 362.00K | 261.00K | 263.00K | 466.00K |
| Other Operating Activities | -9.00K | 78.00K | 127.00K | -128.00K | 167.00K | 9.00K |
| Change in Accounts Payable | -471.00K | 543.00K | 191.00K | -469.00K | -58.00K | 393.00K |
| Change in Unearned Revenue | -409.00K | -405.00K | -349.00K | -743.00K | -810.00K | 1.40M |
| Change in Other Net Operating Assets | 752.00K | 295.00K | -109.00K | 269.00K | -433.00K | 639.00K |
| Operating Cash Flow | -9.51M | -8.95M | -7.64M | -8.44M | -10.80M | -9.86M |
| Capital Expenditures | -2.00K | -2.00K | -5.00K | -2.00K | -9.00K | -11.00K |
| Investment in Securities | -4.00M | 1.50M | 500.00K | 9.51M | -14.50M | |
| Investing Cash Flow | -4.00M | -2.00K | 1.50M | 498.00K | 9.50M | -14.51M |
| Issuance of Common Stock | 10.04M | 9.64M | 7.22M | 9.14M | 21.76M | |
| Other Financing Activities | -512.00K | -1.31M | ||||
| Financing Cash Flow | 10.04M | 9.64M | 6.71M | 9.14M | 20.46M | |
| Foreign Exchange Rate Adjustments | 1.00K | 10.00K | -22.00K | 98.00K | -113.00K | 34.00K |
| Net Cash Flow | -3.47M | 703.00K | 547.00K | 1.30M | -1.41M | -3.88M |
| Free Cash Flow | -9.51M | -8.95M | -7.64M | -8.44M | -10.81M | -9.87M |
| Free Cash Flow Margin | -2,348.89% | -2,210.12% | -1,133.83% | -1,136.20% | -1,334.57% | -1,156.98% |
| Free Cash Flow Per Share | -3.24 | -5.44 | -10.54 | -19.81 | -39.76 | -53.53 |
| Levered Free Cash Flow | -5.58M | -4.99M | -4.82M | -5.12M | -6.51M | -5.98M |
| Unlevered Free Cash Flow | -5.58M | -4.99M | -4.82M | -5.12M | -6.51M | -5.98M |
| Cash Interest Paid | 18.00K | |||||
| Change in Working Capital | -128.00K | 433.00K | -267.00K | -943.00K | -1.30M | 2.43M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 5.20M | 24.64M | 15.56M | 8.84M | 19.49M | 38.55M |
| Enterprise Value | -1.42M | 17.91M | 10.73M | 485.27K | 8.61M | 24.48M |
| Last Close Price | 1.62 | 4.00 | 32.50 | 44.00 | 122.60 | 258.00 |
| PS Ratio | 12.54 | 60.84 | 23.09 | 11.90 | 24.06 | 45.20 |
| PB Ratio | 1.05 | 4.41 | 2.86 | 1.42 | 4.36 | 2.68 |
| P/TBV Ratio | 1.05 | 4.41 | 2.86 | 1.42 | 4.36 | 2.68 |
| EV/Sales Ratio | 44.23 | 15.92 | 0.65 | 10.63 | 28.70 | |
| Debt / Equity Ratio | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
| Net Debt / Equity Ratio | -1.44 | -1.51 | -1.43 | -1.42 | -1.77 | -1.32 |
| Net Debt / EBITDA Ratio | 0.72 | 0.85 | 0.96 | 1.09 | 0.79 | 1.48 |
| Net Debt / FCF Ratio | 0.73 | 0.95 | 1.02 | 1.05 | 0.73 | 1.93 |
| Asset Turnover | 0.05 | 0.04 | 0.07 | 0.08 | 0.06 | 0.06 |
| Quick Ratio | 3.17 | 3.13 | 3.84 | 4.42 | 3.19 | 7.01 |
| Current Ratio | 3.60 | 3.46 | 4.38 | 4.91 | 3.66 | 7.35 |
| Return on Equity (ROE) | -211.37% | -178.24% | -134.94% | -142.49% | -107.91% | -123.34% |
| Return on Assets (ROA) | -77.12% | -66.75% | -53.18% | -53.15% | -42.73% | -53.91% |
| Return on Capital Employed (ROCE) | -166.90% | -146.70% | -115.00% | -102.80% | -148.90% | -73.30% |
| Earnings Yield | -373.46% | -39.89% | -50.64% | -86.33% | -52.20% | -32.72% |
| FCF Yield | -187.31% | -36.33% | -49.11% | -95.47% | -55.47% | -25.60% |
| Buyback Yield / Dilution | -196.15% | -126.97% | -70.22% | -56.71% | -47.49% | -54.32% |